Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003618487 | SCV004488650 | uncertain significance | Peutz-Jeghers syndrome | 2022-12-26 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt STK11 protein function. This variant has not been reported in the literature in individuals affected with STK11-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces alanine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 417 of the STK11 protein (p.Ala417Asp). |
Ambry Genetics | RCV004950528 | SCV005515504 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-11-14 | criteria provided, single submitter | clinical testing | The c.1250C>A (p.A417D) alteration is located in exon 9 (coding exon 9) of the STK11 gene. This alteration results from a C to A substitution at nucleotide position 1250, causing the alanine (A) at amino acid position 417 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |